doi: 10.1002/epd2.20321.
- PMID: 39641913
- DOI: 10.1002/epd2.20321
Abstract
Epilepsy with myoclonic-atonic seizures (EMAS) is an early childhood epilepsy syndrome with an explosive onset of multiple seizure types in a previously healthy child. EMAS often evolves to a drug-resistant epileptic encephalopathy before a variable degree of remission around 3 years from onset. Highly purified cannabidiol (CBD, available in United States as Epidiolex®) has demonstrated efficacy and tolerability as an adjunct in medically refractory EMAS. We present two cases of medically refractory EMAS achieving rapid seizure freedom (7-30 days) with CBD, illustrating CBD as a potential effective monotherapy in EMAS.
Keywords: astatic seizure; atonic seizure; cannabidiol; doose syndrome; epilepsy with myoclonic astatic (atonic) seizures; epileptic encephalopathy; medically refractory epilepsy.
© 2024 International League Against Epilepsy.
References
REFERENCES
-
- Specchio N, Wirrell EC, Scheffer IE, Nabbout R, Riney K, Samia P, et al. International league against epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE task force on nosology and definitions. Epilepsia. 2022;63:1398–1442.
-
- Caraballo R, Valenzuela GR, Fortini S, Espeche A, Gamboni B, Silva W, et al. Cannabidiol in children with treatment‐resistant epilepsy with myoclonic‐atonic seizures. Epilepsy Behav. 2023;143:109245.
-
- Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, Filloux F, et al. Open‐label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018;86:131–137.
-
- Caraballo R, Reyes G, Demirdjian G, Huaman M, Gutierrez R. Long‐term use of cannabidiol‐enriched medical cannabis in a prospective cohort of children with drug‐resistant developmental and epileptic encephalopathy. Seizure. 2022;95:56–63.
-
- Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome. N Engl J Med. 2018;378(20):1888–1897.
